Inhibrx Biosciences, Inc.
INBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $521,299 | $220,728 | $216,397 | $222,929 |
| - Cash | $153,088 | $186,567 | $216,520 | $152,596 |
| + Debt | $6,988 | $7,510 | $106,530 | $8,048 |
| Enterprise Value | $375,199 | $41,671 | $106,407 | $78,381 |
| Revenue | $0 | $1,300 | $0 | $100 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | -$582 | $638 | -$675 | -$589 |
| % Margin | – | 49.1% | – | -589% |
| EBITDA | -$31,493 | -$24,850 | -$39,947 | -$47,176 |
| % Margin | – | -1,911.5% | – | -47,176% |
| Net Income | -$35,256 | -$28,654 | -$43,311 | -$47,865 |
| % Margin | – | -2,204.2% | – | -47,865% |
| EPS Diluted | -2.28 | -1.85 | -2.8 | -3.31 |
| % Growth | -23.2% | 33.9% | 15.4% | – |
| Operating Cash Flow | -$33,824 | -$29,953 | -$35,895 | -$43,720 |
| Capital Expenditures | -$10 | $0 | -$21 | -$16 |
| Free Cash Flow | -$33,834 | -$29,953 | -$35,916 | -$43,736 |